Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 23;10(4):749.
doi: 10.3390/biomedicines10040749.

Is There a Best First Line Biological/Small Molecule in IBD: Are We Ready for Sequencing?

Gustavo Drügg Hahn  1   2 , Petra Anna Golovics  1   3 , Panu Wetwittayakhlang  1   4 , Alex Al Khoury  5 , Talat Bessissow  1 , Peter Laszlo Lakatos  1   6
Affiliations
Review

Is There a Best First Line Biological/Small Molecule in IBD: Are We Ready for Sequencing?

Gustavo Drügg Hahn et al. Biomedicines. .

Abstract

Inflammatory bowel disease (IBD) is a chronic, life-long inflammatory condition of the gastrointestinal tract. Treatment strategy depends on the severity of the disease course. IBD physicians need to be aware of the life-long treatment options available. The goal is not only to achieve clinical remission but to halt or stabilize the chronic inflammation in the intestines to prevent further structural damage. Therefore, the use of early biologic therapy is recommended in moderate-to-severe IBD patients. However, in the last decade, use of therapeutic drug monitoring has increased considerably, opening an opportunity for sequencing. This review summarizes the available evidence on biologic and small molecules therapy in Crohn's disease (CD) and ulcerative colitis (UC) in different clinical scenarios, including perianal CD, the elderly, extra intestinal manifestations, and pregnancy.

Keywords: biologic therapy; biologic-naïve; inflammatory bowel disease; small molecule.

PubMed Disclaimer

Conflict of interest statement

G.D.H. declares no conflict of interest. P.A.G. has been a speaker for AbbVie, Takeda, Fresenius, Ferring. P.W. has been a speaker and/or advisory board member: Takeda, Pfizer, Janssen, Ferring, A. Menerini, and M.S.D. A.A.K. declares no conflict of interest. T.B. has been a speaker or advisory board member for Takeda, Janssen, Abbvie, Merck, Pfizer, Pendopharm, Ferring, Shire, Sandoz, B.M.S., Roche, Fresenius Kabi, Viatris. P.L.L. has been a speaker and/or advisory board member for AbbVie, Arena, Falk Pharma GmbH, Ferring, Genetech, Janssen, Kyowa Hakko Kirin Pharma, Mitsubishi Tanabe Pharma Corporation, M.S.D., Pfizer, Roche, Shire, Takeda and Tillots, and has received unrestricted research grants from AbbVie, M.S.D. and Pfizer.

References

    1. Click B., Regueiro M. A Practical Guide to the Safety and Monitoring of New IBD Therapies. Inflamm. Bowel Dis. 2019;25:831–842. doi: 10.1093/ibd/izy313. - DOI - PMC - PubMed
    1. Seyed Tabib N.S., Madgwick M., Sudhakar P., Verstockt B., Korcsmaros T.V.S. Big data in IBD: Big progress for clinical practice. Gut. 2020;69:1520–1532. doi: 10.1136/gutjnl-2019-320065. - DOI - PMC - PubMed
    1. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.-F., Rachmilewitz D., Wolf D.C., Olson A., Bao W., et al. Manteniance infliximab in Crohn’s disease: The ACCENT I randomised trial. Lancet. 2002;359:1541–1549. doi: 10.1016/S0140-6736(02)08512-4. - DOI - PubMed
    1. Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., Olson A., Johanns J., Travers S., Rachmilewitz D., Hanauer S.B., Lichtenstein G.R., et al. Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis. N. Engl. J. Med. 2005;353:2462–2476. doi: 10.1056/NEJMoa050516. - DOI - PubMed
    1. Colombel J., Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Panaccione R., Schreiber S., Byczkowski D., Li J., Kent J.D., et al. Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial. Gastroenterology. 2007;132:52–65. doi: 10.1053/j.gastro.2006.11.041. - DOI - PubMed

LinkOut - more resources